Potent β-lactam inhibitors of human cytomegalovirus protease

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 5, 1998, Pages 379-387

  Yoakim, C ^a   Ogilvie, W W ^a   Cameron, D R ^a   Chabot, C ^a   Grand Maitre C ^a   Guse, I ^a   Hache B ^a   Kawai, S ^a   Naud, J ^a   O'Meara, J A ^a   Plante, R ^a   Deziel R ^a  

^a Boehringer Ingelheim Canada   (Canada)

Author keywords

Human cytomegalovirus; Protease inhibitors; lactams

Indexed keywords

ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; MONOBACTAM; PROTEINASE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN CYTOMEGALOVIRUS; PRIORITY JOURNAL;

EID: 17344377814     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900502     Document Type: Article

References (31)

1. Alford CA & Britt WJ (1993) Cytomegalovirus. In The Human Herpesvirus, pp. 227-255. Edited by RJ Whitley & C Lopez. New York: Raven.
2. Baldwin JE, Adlington RM, Gollins DW & Schofield CJ (1990) Stereospecific synthesis of dealanylalahopcin. Tetrahedron 46:4733-4748.
3. Beak P, Wu S, Yum KE & Jun MY (1994) Intramolecular cyclization of α-lithioamine synthetic equivalents: convenient synthesis of 3-, 5-, and 6-membered ring heterocyclic nitrogen compound and elaborations of 3-membered ring systems. Journal of Organic Chemistry 59:276-277.
4. Bonneau PR, Plouffe C, Pelletier A, Wernic D & Poupart M-A (1998) Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies. Analytical Biochemistry 255:59-65.
5. Borthwick AD, Weingarten G, Haley TM, Tomaszewski M, Wang W, Hu Z, Bedard J, Jin H, Yuen L & Mansour TS (1998) Design and synthesis of monocyclic β-lactams as mechanism based inhibitors of human cytomegalovirus protease. Bioorganic & Medicinal Chemistry Letters 8:365-370.
6. Chen P, Tsuge H, Almassy RJ, Gribskov CL, Katoh S, Vanderpool PL, Margosiak SA, Pinko C, Matthews DA & Kan C-C (1996) Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 86:835-843.
7. Denizot F & Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. Journal of Immunological Methods 89:271-277.
8. Dewar MJS, Zoebisch EG, Healy EF & and Stewart JJP (1985) AM1: A new general purpose quantum mechanical model. Journal of the American Chemical Society 107:3902.
9. o with monocyclic β-lactams. Bioorganic & Medicinal Chemistry Letters (in press).
10. Dô F, Massariol M-J, Lagacé L, Bailey M, Halmos T, Déziel R & Cordingley MG (1997) Inhibition of human cytomegalovirus protease precursor and assembly protein. Processing by peptidomimetic inhibitors of HCMV protease. FASEB Journal 11:A1225.
11. Dormoy JR (1982) Synthesis of L-3,4-didehydroproline: favored orientation in the key-step elimination reaction. Synthesis 753-756.
12. Finke PE, Shah SK, Fletcher DS, Ashe BM, Brause KA, Chandelier GO, Dellea PS, Hand KM, Maycock AL & Osinga DG, Underwood DJ, Weston H, Davies P & Doherty JB (1995) Orally active β-lactam inhibitors of human leukocyte elastase. Stereospecific synthesis and structure - activity relationships for 3,3-dialkylazetidin-2-ones. Journal of Medicinal Chemistry. 38:2449-2462.
13. Gao M, Matusick-Kumar L, Hurlburt W, DiTusa SF, Newcomb WW, Brown JC, McCann III PJ, Deckmann I & Colonno RJ (1994) The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. Journal of Virology 68:3702-3712.
14. Gibson W, Welch AR & Hall MRT (1994) Assemblin, a herpes virus serine maturational proteinase and new molecular target for antivirals. Perspectives in Drug Discovery and Design 2:413-426.
15. Gold E & Nankervis GA (1982) Viral Infections of Humans: Epidemiology and control, 2nd edn, pp. 167-186 Edited by AS Evans, New York: Plenum.
16. Holwerda BC, Wittwer AJ, Duffin KL, Smith C, Toth MV, Carr LS, Weigand RC & Bryant ML (1994) Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. Journal of Biological Chemistry 269:25911-25915.
17. Holwerda BC (1997) Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Research 35:1-21.
18. Hughes DL (1992) The Mitsunobu reaction. Organical Reactions 42:335-656.
19. Markham A & Faulds D (1994) Ganciclovir-an update of its therapeutic use in cytomegalovirus. Drugs 48:45-484.
20. Ogilvie W, Bailey M, Poupart M-A, Abraham A, Bhavsar A, Bonneau P, Bordeleau J, Bousquet Y, Chabot C, Duceppe J-S, Fazal G, Goulet S, Grand-Maître C, Guse I, Halmos T, Lavallée P, Leach M, Malenfant E, O'Meara J, Plante R, Plouffe C, Poirier M, Soucy F, Yoakim C & Déziel R (1997) Peptidomimetic inhibitors of the human cytomegalovirus protease. Journal of Medicinal Chemistry 40:4113-4135.
21. Preston VG, Rixon FJ, McDougall IM, McGregor M & Al Kobaisi MF (1992) Processing of the herpes simplex virus assembly protein ICP35 near its carboxy terminal end requires the product of the whole of the UL26 reading frame. Virology 186:87-98.
22. Qiu X, Culp JS, DiLella AG, Hellmig B, Hoog SS, Janson CA, Smith WW & Abdel-Meguid SS (1996) Unique fold and active site in cytomegalovirus protease. Nature 383:275-279.
23. Rawlings ND & Barrett AJ (1994) Families of serine proteases. Methods Enzymology 244:19-61.
24. Rodriguez M, Llinares M, Doulut S, Heitz A & Martinez J (1991) A facile synthesis of chiral N-protected β-amino alcohols. Tetrahedron Letters 32:923-926.
25. Shieh N-S, Kurumball RG, Stevens AM, Stegeman RA, Sturman EJ, Pak JY, Wittwer AJ, Palmier MO, Wiegand RC, Holwerda BC & Stallings WC (1996) Three-dimensional structure of human cytomegalovirus protease. Nature 383:279-282.
26. Stevens JT, Mapelli C, Tsao J, Hail M, O'Boyle D, Weinheimer SP & Dilanni CL (1994) In vitro proteolytic activity and active-site identification of the human cytomegalovirus protease. European Journal of Biochemistry 226:361-367.
27. Tong L, Qian C, Massariol M-J, Bonneau PR, Cordingley MG & Lagacé L (1996) A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 383:272-275.
28. Wagstaff AJ & Bryson HM (1994) Foscarnet - a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48:199-226.
29. Welch AR, McNally LM, Hall MRT & Gibson W (1993) Herpesvirus proteinase: site-directed mutagenesis used to study maturational, release, and inactivation cleavage sites of precursor and to identify a possible catalytic site serine and histidine. Journal of Virology 67:7360-7372.
30. Wu S, Lee S & Beak P (1996) Asymmetric deprotonation by BuLi/(-) sparteine: convenient and highly enantioselective syntheses of (S)-2-aryl-Boc-pyrrolidine. Journal of the American Chemical Society 118:715-721.
31. Yoakim C, Ogilvie W, Cameron D, Chabot C, Guse I, Haché B, Naud J, O'Meara J, Plante R & Déziel R (1998) β-Lactam derivatives as inhibitors of human cytomegalovirus protease. Journal of Medicinal Chemistry (in press).